ID   HuCC-A1
AC   CVCL_M255
SY   HuCCA-1; HuCCA1
DR   ChEMBL-Cells; CHEMBL4513113
DR   ChEMBL-Targets; CHEMBL4513129
DR   JCRB; JCRB1657
DR   PubChem_Cell_line; CVCL_M255
DR   Wikidata; Q54896723
RX   CelloPub=CLPUB00275;
RX   PubMed=1666951;
RX   PubMed=9031402;
RX   PubMed=12587840;
RX   PubMed=15048994;
RX   PubMed=16475706;
RX   PubMed=20069059;
RX   PubMed=31077409;
RX   PubMed=35640676;
WW   http://www2.cri.or.th/lab/biochemistry/res_act
CC   Population: Southeast Asian; Thai.
CC   Doubling time: ~55 hours (PubMed=1666951).
CC   Omics: Secretome proteome analysis.
CC   Derived from site: In situ; Bile duct; UBERON=UBERON_0002394.
ST   Source(s): JCRB
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 8
ST   D16S539: 11,12
ST   D5S818: 12
ST   D7S820: 10,11
ST   TH01: 9
ST   TPOX: 9
ST   vWA: 14,19
DI   NCIt; C35417; Intrahepatic cholangiocarcinoma
DI   NCIt; C27769; Opisthorchis viverrini-related cholangiocarcinoma
DI   ORDO; Orphanet_70567; Cholangiocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   54Y
CA   Cancer cell line
DT   Created: 05-11-13; Last updated: 29-06-23; Version: 18
//
RX   CelloPub=CLPUB00275;
RA   Zach S., Birgin E., Ruckert F.;
RT   "Primary cholangiocellular carcinoma cell lines.";
RL   J. Stem Cell Res. Transplant. 2:1013-1013(2015).
//
RX   PubMed=1666951;
RA   Sirisinha S., Tengchaisri T., Boonpucknavig S., Prempracha N.,
RA   Ratanarapee S., Pausawasdi A.;
RT   "Establishment and characterization of a cholangiocarcinoma cell line
RT   from a Thai patient with intrahepatic bile duct cancer.";
RL   Asian Pac. J. Allergy Immunol. 9:153-157(1991).
//
RX   PubMed=9031402;
RA   Sriurairatana S., Tengchaisri T., Sirisinha S.;
RT   "Ultrastructural characteristics of liver fluke associated human
RT   cholangiocarcinoma cell lines.";
RL   Southeast Asian J. Trop. Med. Public Health 27:57-62(1996).
//
RX   PubMed=12587840;
RA   Panichakul T., Wanun T., Reutrakul V., Sirisinha S.;
RT   "Synergistic cytotoxicity and apoptosis induced in human
RT   cholangiocarcinoma cell lines by a combined treatment with tumor
RT   necrosis factor-alpha (TNF-alpha) and triptolide.";
RL   Asian Pac. J. Allergy Immunol. 20:167-173(2002).
//
RX   PubMed=15048994; DOI=10.1002/pmic.200300651;
RA   Srisomsap C., Sawangareetrakul P., Subhasitanont P., Panichakul T.,
RA   Keeratichamroen S., Lirdprapamongkol K., Chokchaichamnankit D.,
RA   Sirisinha S., Svasti J.;
RT   "Proteomic analysis of cholangiocarcinoma cell line.";
RL   Proteomics 4:1135-1144(2004).
//
RX   PubMed=16475706;
RA   Panichakul T., Intachote P., Wongkajornsilp A., Sripa B., Sirisinha S.;
RT   "Triptolide sensitizes resistant cholangiocarcinoma cells to
RT   TRAIL-induced apoptosis.";
RL   Anticancer Res. 26:259-265(2006).
//
RX   PubMed=20069059; DOI=10.1155/2010/437143;
RA   Srisomsap C., Sawangareetrakul P., Subhasitanont P.,
RA   Chokchaichamnankit D., Chiablaem K., Bhudhisawasdi V., Wongkham S.,
RA   Svasti J.;
RT   "Proteomic studies of cholangiocarcinoma and hepatocellular carcinoma
RT   cell secretomes.";
RL   J. Biomed. Biotechnol. 2010:437143.1-437143.18(2010).
//
RX   PubMed=31077409; DOI=10.1002/hep.30704;
RA   Sittithumcharee G., Suppramote O., Vaeteewoottacharn K.,
RA   Sirisuksakun C., Jamnongsong S., Laphanuwat P., Suntiparpluacha M.,
RA   Matha A., Chusorn P., Buraphat P., Kakanaporn C., Charngkaew K.,
RA   Silsirivanit A., Korphaisarn K., Limsrichamrern S., Tripatara P.,
RA   Pairojkul C., Wongkham S., Sampattavanich S., Okada S.,
RA   Jirawatnotai S.;
RT   "Dependency of cholangiocarcinoma on cyclin D-dependent kinase
RT   activity.";
RL   Hepatology 70:1614-1630(2019).
//
RX   PubMed=35640676; DOI=10.1016/j.ajpath.2022.05.007;
RA   Isidan A., Yenigun A., Soma D., Aksu E., Lopez K., Park Y.,
RA   Cross-Najafi A., Li P., Kundu D., House M.G., Chakraborty S.,
RA   Glaser S., Kennedy L., Francis H., Zhang W.-J., Alpini G.D., Ekser B.;
RT   "Development and characterization of human primary cholangiocarcinoma
RT   cell lines.";
RL   Am. J. Pathol. 192:1200-1217(2022).
//